Karyopharm Therapeutics Inc. announced that Sohanya Cheng has been promoted to Chief Commercial Officer. She will be responsible for leading the Company's commercial strategy and operations, including the continued commercialization of XPOVIO® (selinexor). Ms. Cheng joined Karyopharm in 2021 as Senior Vice President of Sales and Commercial Operations.

Ms. Cheng has 18 years of biopharmaceutical commercialization and research experience, predominately in oncology. Prior to joining Karyopharm, she served as Vice President, Head of Marketing and Corporate Affairs at Arrowhead Pharmaceuticals.